SETTLEMENT AGREEMENT

I. PARTIES

This Settlement Agreement (Agreement) is entered into among the United States of America, acting through the United States Department of Justice and the United States Attorney’s Office for the Eastern District of Pennsylvania, the Office of Inspector General of the United States Department of Health and Human Services ("OIG-HHS"), the TRICARE Management Activity ("TMA"), and the United States Office of Personnel Management ("OPM") (collectively the “United States”); James Wetta ("Wetta"); Stephan Kruszewski, M.D. ("Kruszewski"); and AstraZeneca LP and AstraZeneca Pharmaceuticals LP (collectively, "AstraZeneca"), through their authorized representatives. Collectively, all of the above will be referred to as “the Parties.”

II. PREAMBLE

As a preamble to this Agreement, the Parties agree to the following:

A. AstraZeneca LP and AstraZeneca Pharmaceuticals LP are Delaware limited partnerships with their principal places of business in Wilmington, Delaware. At all relevant times herein, AstraZeneca distributed, marketed and sold pharmaceutical products in the United States, including a drug sold under the trade name of Seroquel.


C. On September 8, 2006, Kruszewski filed a qui tam action in the United States District Court for the Eastern District of Pennsylvania captioned United States of America ex rel. Stephan Kruszewski v. AstraZeneca Pharmaceuticals LP, Civil Action No. 06-4004
(hereinafter "Civil Action II"). Civil Action I and Civil Action II hereinafter may be referred to collectively as the "Civil Actions."

D. AstraZeneca has entered or will be entering into separate settlement agreements, described in Paragraph 1(b), below (hereinafter referred to as the "Medicaid State Settlement Agreements") with certain states and the District of Columbia in settlement of the Covered Conduct. States with which AstraZeneca executes a Medicaid State Settlement Agreement in the form to which AstraZeneca and the National Association of Medicaid Fraud Control Units ("NAMFCU") Negotiating Team have agreed, or in a form otherwise agreed to by AstraZeneca and an individual State, shall be defined as "Medicaid Participating States."

E. The United States and the Medicaid Participating States allege that AstraZeneca caused claims for payment for Seroquel to be submitted to the Medicaid Program, Title XIX of the Social Security Act, 42 U.S.C. §§ 1396-1396v (the Medicaid Program).

F. The United States further alleges that AstraZeneca caused claims for payment for Seroquel to be submitted to the Medicare Program, Title XVIII of the Social Security Act, 42 U.S.C. § 1395-1395hhh; the TRICARE program, 10 U.S.C. §§ 1071-1109; the Federal Employees Health Benefits Program ("FEHBP"), 5 U.S.C. §§ 8901-8914; the Federal Employees Compensation Act Program, 5 U.S.C. § 8101 et seq; and caused purchases of Seroquel by the Department of Veterans’ Affairs ("DVA"), Department of Defense, and the Bureau of Prisons ("BOP") (collectively, the "other Federal Health Care Programs").

G. The United States contends that it has certain civil claims, as specified in Paragraph 2, below, against AstraZeneca for engaging in the following conduct during the period January 1, 2001 through December 31, 2006 (hereinafter referred to as the "Covered Conduct"):
(1) AstraZeneca promoted the sale and use of Seroquel to psychiatrists, other physicians (including primary care physicians) and other health care professionals in pediatric and primary care physician offices, in long-term care facilities and hospitals and in prisons for certain uses that were not approved by the Food and Drug Administration as safe and effective for those uses (including aggression, Alzheimer’s disease, anger management, anxiety, attention deficit hyperactivity disorder, bipolar maintenance, dementia, depression, mood disorder, post-traumatic stress disorder, and sleeplessness) ("unapproved uses"). AstraZeneca also promoted the unapproved uses by engaging in the following conduct: AstraZeneca improperly and unduly influenced the content of and speakers in company-sponsored Continuing Medical Education programs; engaged doctors to give promotional speaker programs it controlled on unapproved uses for Seroquel; engaged doctors to conduct studies on unapproved uses of Seroquel; recruited doctors to serve as authors of articles largely prepared by medical literature companies about studies they did not conduct on unapproved uses of Seroquel; and, used those studies and articles as the basis for promotional messages about unapproved uses of Seroquel. These unapproved uses were not medically accepted indications for which the United States and the state Medicaid programs provided coverage for Seroquel.

(2) AstraZeneca offered and paid illegal remuneration to doctors: (a) it recruited to conduct studies for unapproved uses, (b) it recruited to serve as authors of articles written by AstraZeneca and its agents about these unapproved uses of Seroquel, (c) to travel to resort locations to "advise" AstraZeneca about marketing messages for unapproved uses of Seroquel, and (d) it recruited to give promotional lectures to other health care professionals about unapproved and unaccepted uses of Seroquel. The United States contends that these payments were intended to induce the doctors to promote and/or prescribe Seroquel for unapproved uses in violation of the Federal Anti-Kickback Statute, 42 U.S.C. § 1320-7b(b).

As a result of the foregoing conduct, the United States contends that AstraZeneca knowingly caused false or fraudulent claims for Seroquel to be submitted to, or caused purchases by, Medicaid, Medicare and the other Federal Health Care Programs.
H. The United States also contends that it has certain administrative claims against AstraZeneca, as set forth in Paragraphs 4 through 6, below, for engaging in the Covered Conduct.

I. This Agreement is made in compromise of disputed claims. This Agreement is neither an admission of facts or liability by AstraZeneca nor a concession by the United States that its claims are not well founded. AstraZeneca expressly denies the allegations of the United States, the Medicaid Participating States, Wetta and Kruszewski as set forth herein and in Civil Action I and Civil Action II and denies that it has engaged in any wrongful conduct. Neither this Agreement, its execution, nor the performance of any obligation under it, including any payment, nor the fact of settlement, are intended to be, or shall be understood as, an admission of liability or wrongdoing, or other expression reflecting on the merits of the dispute by AstraZeneca.

J. To avoid the delay, uncertainty, inconvenience, and expense of protracted litigation of the above claims, the Parties reach a full and final settlement pursuant to the Terms and Conditions below.

III. TERMS AND CONDITIONS

NOW, THEREFORE, in reliance on the representations contained herein and in consideration of the mutual promises, covenants, and obligations in this Agreement, and for good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:

1. AstraZeneca agrees to pay to the United States and the Medicaid Participating States, collectively, the sum of Five Hundred and Twenty Million Dollars ($520,000,000), plus
accrued interest at the rate of 3% per annum from December 1, 2009, and continuing until and including the date of payment (the “Settlement Amount”). Payments shall be made as follows:

(a) AstraZeneca shall pay to the United States the sum of $301,907,007, plus accrued interest as set forth above (“Federal Settlement Amount”). The Federal Settlement Amount shall be paid by electronic funds transfer pursuant to written instructions from the United States no later than ten (10) business days after the Effective Date of this Agreement.

(b) AstraZeneca shall pay to the Medicaid Participating States the sum of $218,092,993, plus accrued interest as set forth above (“Medicaid State Settlement Amount”) pursuant to written instructions from the NAMFCU Negotiating Team and under the terms and conditions of the Medicaid State Settlement Agreements that AstraZeneca will enter into with the Medicaid Participating States.

(c ) Contingent upon the United States receiving the Federal Settlement Amount from AstraZeneca, the United States agrees to pay, as soon as feasible after receipt, to Wetta $45,286,051, plus a pro rata share of the actual accrued interest paid to the United States by AstraZeneca, as set forth in Paragraph 1(a), above, (“Relator’s Share”) as relator’s share of the proceeds pursuant to 31 U.S.C. § 3730(d). No other relator payments of any sort shall be made by the United States to Wetta and/or Kruszewski with respect to the matters covered by this Agreement.

(d) Wetta and Kruszewski have entered into a separate agreement under which Kruszewski will receive a portion of the Relator’s Share.

2. Subject to the exceptions in Paragraph 7, below, in consideration of the obligations of AstraZeneca in this Agreement, conditioned upon AstraZeneca’s full payment of
the Settlement Amount, the United States (on behalf of itself, its officers, agents, agencies, and departments) agrees to release AstraZeneca, together with AstraZeneca’s predecessors, current and former parents, affiliates, direct and indirect subsidiaries, brother or sister entities, divisions, transferees, successors and assigns, and all of their current or former directors, officers and employees (hereinafter, collectively “AstraZeneca Releasees”) from any civil or administrative monetary claim the United States has or may have for the Covered Conduct under the False Claims Act, 31 U.S.C. §§ 3729-3733; the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a; the Program Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-3812; any statutory provision for which the Civil Division of the Department of Justice has actual and present authority to assert and compromise pursuant to 28 C.F.R. Part O, Subpart I, Section 0.45(D); or the common law theories of payment by mistake, unjust enrichment, fraud, disgorgement of illegal profits, and, if applicable, breach of contract.

3. In consideration of the obligations of AstraZeneca in this Agreement, conditioned upon AstraZeneca’s full payment of the Settlement Amount, Wetta and Kruszewski, for themselves and for their heirs, successors, attorneys, agents, and assigns, fully and finally release the AstraZeneca Releasees from any claim the United States has, may have or could have asserted related to the Covered Conduct, and from all liability, claims, demands, actions or causes of action whatsoever existing as of the Effective Date of this Agreement, whether known or unknown, fixed or contingent, in law or in equity, in contract or in tort, under any federal or state statute or regulation or that they or their heirs, successors, attorneys, agents and assigns otherwise would have standing to bring, including any liability arising from the filing of the Civil Actions, except for any claims they may have under 31 U.S.C. § 3730(d) and/or 31 U.S.C.
§ 3730(h).

4. In consideration of the obligations of AstraZeneca in this Agreement and the Corporate Integrity Agreement ("CIA"), entered into between OIG-HHS and AstraZeneca, conditioned upon AstraZeneca’s full payment of the Settlement Amount, OIG-HHS agrees to release and refrain from instituting, directing, or maintaining any administrative action seeking exclusion from Medicare, Medicaid, and other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)), against AstraZeneca under 42 U.S.C. § 1320a-7a (Civil Monetary Penalties Law) or 42 U.S.C. § 1320a-7(b)(7) (permissive exclusion for fraud, kickbacks, and other prohibited activities) for the Covered Conduct, except as reserved in Paragraph 7 below, and as reserved in this Paragraph. The OIG-HHS expressly reserves all rights to comply with any statutory obligations to exclude AstraZeneca from Medicare, Medicaid, and other Federal health care programs under 42 U.S.C. § 1320a-7(a) (mandatory exclusion) based upon the Covered Conduct. Nothing in this Paragraph precludes the OIG-HHS from taking action against entities or persons, or for conduct and practices, for which claims have been reserved in Paragraph 7, below.

5. In consideration of the obligations of AstraZeneca set forth in this Agreement, conditioned upon AstraZeneca’s full payment of the Settlement Amount, TMA agrees to release and refrain from instituting, directing, or maintaining any administrative action seeking exclusion from the TRICARE Program, against AstraZeneca under 32 C.F.R. § 199.9 for the Covered Conduct, except as reserved in Paragraph 7, below, and as reserved in this Paragraph. TMA expressly reserves authority to exclude AstraZeneca under 32 C.F.R. §§ 199.9 (f)(1)(i)(A), (f)(1)(i)(B), and (f)(1)(iii), based upon the Covered Conduct. Nothing in this Paragraph
precludes TMA or the TRICARE Program from taking action against entities or persons, or for conduct and practices, for which claims have been reserved in Paragraph 7, below.

6. In consideration of the obligations of AstraZeneca in this Agreement, conditioned upon AstraZeneca’s full payment of the Settlement Amount, OPM agrees to release and refrain from instituting, directing, or maintaining any administrative action, against AstraZeneca under 5 U.S.C. § 8902a or 5 C.F.R. Part 919 or Part 970 for the Covered Conduct, except as reserved in Paragraph 7, below and except as required by 5 U.S.C. §8902a(b). Nothing in this Paragraph precludes OPM from taking action against entities or persons, or for conduct and practices, for which claims have been reserved in Paragraph 7, below.

7. Notwithstanding any term of this Agreement, the following claims of the United States are specifically reserved and excluded from the scope and terms of this Agreement as to any entity or person (including AstraZeneca, Wetta and/or Kruszewski):

   (a) Any civil, criminal, or administrative liability arising under Title 26, U.S. Code (Internal Revenue Code);

   (b) Any criminal liability;

   (c) Except as explicitly stated in this Agreement, any administrative liability, including mandatory exclusion from Federal health care programs;

   (d) Any liability to the United States (or its agencies) for any conduct other than the Covered Conduct;

   (e) Any liability based upon such obligations as are created by this Agreement;

   (f) Any liability for express or implied warranty claims or other claims for

Settlement Agreement Between United States and AstraZeneca, Inc. 

-8-
defective or deficient products or services, including quality of goods and services;

(g) Any liability for personal injury or property damage or for other consequential damages arising from the Covered Conduct; and

(h) Any liability for failure to deliver goods or services due.

8. Wetta and Kruszewski and their heirs, successors, attorneys, agents, and assigns agree not to object to this Agreement and agree and confirm that this Agreement is fair, adequate, and reasonable under all the circumstances, pursuant to 31 U.S.C. § 3730(c)(2)(B) and, conditioned upon the United States’ payment of the Relator’s Share, as set forth in Paragraph 1(c), above, Wetta and Kruszewski, for themselves individually, and for their heirs, successors, agents, and assigns, fully and finally release, waive, and forever discharge the United States, and its officers, agents, and employees, from any claims arising from or relating to 31 U.S.C. § 3730; from any claims arising from the filing of Civil Action I and/or Civil Action II; and from any other claims for a share of the Settlement Amount or payment of any sort from the United States relating to the Settlement Agreement or the filing of Civil Action I and/or Civil Action II; and in full settlement of any claims Wetta and/or Kruszewski may have under this Agreement. This Agreement does not resolve or in any manner affect any claims the United States has or may have against Wetta and/or Kruszewski arising under Title 26, U.S. Code (Internal Revenue Code), or any claims arising under this Agreement.

9. AstraZeneca waives and shall not assert any defenses AstraZeneca may have to any criminal prosecution or administrative action relating to the Covered Conduct that may be based in whole or in part on a contention that, under the Double Jeopardy Clause in the Fifth
Amendment of the Constitution, or under the Excessive Fines Clause in the Eighth Amendment of the Constitution, this Agreement bars a remedy sought in such criminal prosecution or administrative action. Nothing in this paragraph or any other provision of this Agreement constitutes an agreement by the United States concerning the characterization of the Settlement Amount for purposes of the Internal Revenue laws, Title 26 of the United States Code.

10. AstraZeneca fully and finally releases the United States, its agencies, employees, servants, and agents from any claims (including attorney's fees, costs, and expenses of every kind and however denominated) that AstraZeneca has asserted, could have asserted, or may assert in the future against the United States, its agencies, employees, servants, and agents, related to the Covered Conduct and the United States' investigation and prosecution thereof.

11. Conditioned upon Wetta and Kruszewski's compliance with their obligations under this Agreement, AstraZeneca fully and finally releases Wetta and Kruszewski from any claims (including attorney's fees, costs, and expenses of every kind and however denominated) that AstraZeneca has asserted, could have asserted, or may assert in the future against Wetta and/or Kruszewski, related to the Covered Conduct and Wetta and/or Kruszewski's investigation and prosecution thereof, except to the extent related to claims Wetta or Kruszewski may have under 31 U.S.C. § 3730(d) and/or 31 U.S.C. § 3730(h).

12. The Settlement Amount shall not be decreased as a result of the denial of claims for payment now being withheld from payment by any Medicare carrier or intermediary or any other state or Federal payer, related to the Covered Conduct; and AstraZeneca agrees not to resubmit to any Medicare carrier or intermediary or any other state or Federal payer any previously denied claims related to the Covered Conduct, and agrees not to appeal any such
denials of claims.

13. AstraZeneca agrees to the following:

(a) **Unallowable Costs Defined:** that all costs (as defined in the Federal Acquisition Regulation, 48 C.F.R. § 31.205-47; and in Titles XVIII and XIX of the Social Security Act, 42 U.S.C. §§ 1395-1395hhh and 1396-1396v; and the regulations and official program directives promulgated thereunder) incurred by or on behalf of AstraZeneca, its present or former officers, directors, employees, shareholders and agents in connection with the following shall be “Unallowable Costs” on government contracts and under the Medicare Program, Medicaid Program, TRICARE Program, and FEHBP:

(i) the matters covered by this Agreement;

(ii) the United States’ audit(s) and civil and any criminal investigation(s) of the matters covered by this Agreement;

(iii) AstraZeneca’s investigation, defense, and corrective actions undertaken in response to the United States’ audit(s) and civil and any criminal investigation(s) in connection with the matters covered by this Agreement (including attorney’s fees);

(iv) the negotiation and performance of this Agreement;

(v) the payment AstraZeneca makes to the United States pursuant to this Agreement and any payments that AstraZeneca may make to Wetta and/or Kruszewski, including costs and attorneys fees; and

(vi) the negotiation of, and obligations undertaken pursuant to the CIA to:
(a) retain an independent review organization to perform annual reviews as described in Section III of the CIA; and

(b) prepare and submit reports to the OIG-HHS.

However, nothing in this paragraph 13(a)(vi) that may apply to the obligations undertaken pursuant to the CIA affects the status of costs that are not allowable based on any other authority applicable to AstraZeneca. (All costs described or set forth in this Paragraph 13(a) are hereafter “Unallowable Costs.”)

(b) **Future Treatment of Unallowable Costs:** If applicable, these Unallowable Costs shall be separately determined and accounted for by AstraZeneca, and AstraZeneca shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by AstraZeneca or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

(c) **Treatment of Unallowable Costs Previously Submitted for Payment:** If applicable, AstraZeneca further agrees that within 90 days of the Effective Date of this Agreement, it shall identify to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and Medicaid and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph) included in payments previously sought from the United States, or any State Medicaid program, including, but not limited to, payments sought in any cost reports, cost statements, information reports, or payment requests already submitted by AstraZeneca or any of its subsidiaries or affiliates, and shall request, and agree, that such cost reports, cost statements, information reports, or payment requests, even if already settled, be adjusted to account for the
effect of the inclusion of the unallowable costs. AstraZeneca agrees that the United States, at
minimum, shall be entitled to recoup from AstraZeneca any overpayment plus applicable interest
and penalties as a result of the inclusion of such Unallowable Costs on previously-submitted cost
reports, information reports, cost statements, or requests for payment.

Any payments due after the adjustments have been made shall be paid to the
United States pursuant to the direction of the Department of Justice and/or the affected agencies.
The United States reserves its rights to disagree with any calculations submitted by AstraZeneca
or any of its subsidiaries or affiliates on the effect of inclusion of Unallowable Costs (as defined
in this Paragraph) on AstraZeneca or any of its subsidiaries or affiliates’ cost reports, cost
statements, or information reports.

(d) Nothing in this Agreement shall constitute a waiver of the rights of the
United States to audit, examine, or re-examine AstraZeneca’s books and records to determine
that no Unallowable Costs have been claimed in accordance with the provisions of this
Paragraph.

14. This Agreement is intended to be for the benefit of the Parties only. The Parties
do not release any claims against any other person or entity, except to the extent provided for
above or in Paragraph 15 (waiver for beneficiaries paragraph), below.

15. AstraZeneca agrees that it waives and shall not seek payment for any of the health
care billings covered by this Agreement from any health care beneficiaries or their parents,
sponsors, legally responsible individuals, or third party payors based upon the claims defined as
Covered Conduct.

16. AstraZeneca warrants that it has reviewed its financial situation and that it
currently is solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and 548(a)(1)(B)(ii)(I), and shall remain solvent following payment to the United States of the Settlement Amount. Further, the Parties warrant that, in evaluating whether to execute this Agreement, they (a) have intended that the mutual promises, covenants, and obligations set forth constitute a contemporaneous exchange for new value given to AstraZeneca, within the meaning of 11 U.S.C. § 547(c)(1); and (b) have concluded that these mutual promises, covenants, and obligations do, in fact, constitute such a contemporaneous exchange. Further, the Parties warrant that the mutual promises, covenants, and obligations set forth herein are intended to and do, in fact, represent a reasonably equivalent exchange of value that is not intended to hinder, delay, or defraud any entity to which AstraZeneca was or became indebted to on or after the date of this transfer, within the meaning of 11 U.S.C. § 548(a)(1).

17. Upon receipt of the payments described in Paragraph 1, above, the United States and Wetta shall promptly sign and file in Civil Action I a Notice of Intervention and Joint Stipulation of Dismissal with prejudice as to all federal counts in Civil Action I pursuant to the terms and conditions of the Agreement. Upon receipt of the payments described in Paragraph 1, above, Kruszewski shall promptly sign and file in Civil Action II a Notice of Dismissal with prejudice as to all federal counts in Civil Action II pursuant to the terms and conditions of the Agreement.

18. Except as expressly provided to the contrary in this Agreement, each Party shall bear its own legal and other costs incurred in connection with this matter, including the preparation and performance of this Agreement.

19. AstraZeneca represents that this Agreement is freely and voluntarily entered into
without any degree of duress or compulsion whatsoever.

20. Wetta and Kruszewski represent that this Agreement is freely and voluntarily entered into without any degree of duress or compulsion whatsoever.

21. This Agreement is governed by the laws of the United States. The Parties agree that the exclusive jurisdiction and venue for any dispute arising between and among the Parties under this Agreement is the United States District Court for the Eastern District of Pennsylvania, except that disputes arising under the CIA shall be resolved exclusively under the dispute resolution provisions in the CIA.

22. For purposes of construction, this Agreement shall be deemed to have been drafted by all Parties to this Agreement and shall not, therefore, be construed against any Party for that reason in any subsequent dispute.

23. This Agreement constitutes the complete agreement between the Parties. This Agreement may not be amended except by written consent of the Parties.

24. The individuals signing this Agreement on behalf of AstraZeneca represent and warrant that they are authorized by AstraZeneca to execute this Agreement. The individual(s) signing this Agreement on behalf of Wetta and Kruszewski represent and warrant that they are authorized by Wetta and Kruszewski to execute this Agreement. The United States signatories represent that they are signing this Agreement in their official capacities and that they are authorized to execute this Agreement.

25. This Agreement may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same Agreement.

26. This Agreement is binding on AstraZeneca's successors, transferees, heirs, and
assigns.

27. This Agreement is binding on Wetta and Kruszewski's successors, transferees, heirs, and assigns.

28. All parties consent to the United States' disclosure of this Agreement, and information about this Agreement, to the public.

29. This Agreement is effective on the date of signature of the last signatory to the Agreement (Effective Date of this Agreement). Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this Agreement.
THE UNITED STATES OF AMERICA

DATED: 4-27-10 BY: MICHAEL L. LEVY
United States Attorney
United States Attorney’s Office
Eastern District of Pennsylvania

DATED: 4-27-10 BY: VIRGINIA A. GIBSON
First Assistant
United States Attorney’s Office
Eastern District of Pennsylvania

DATED: 4-27-10 BY: MARGARET L. HUTCHINSON
Chief, Civil Division
United States Attorney’s Office
Eastern District of Pennsylvania

DATED: 4-27-10 BY: COLIN CHERICO
Assistant U.S. Attorney
United States Attorney’s Office
Eastern District of Pennsylvania

DATED: __________ BY: PATRICIA L. HANOWER
Trial Attorney
Commercial Litigation Branch
Civil Division
United States Department of Justice

Settlement Agreement Between
United States and AstraZeneca, Inc.

-17-
THE UNITED STATES OF AMERICA

DATED:_______  BY:______________________________

MICHAEL L. LEVY
United States Attorney
United States Attorney’s Office
Eastern District of Pennsylvania

DATED:_______  BY:______________________________

VIRGINIA A. GIBSON
First Assistant
United States Attorney’s Office
Eastern District of Pennsylvania

DATED:_______  BY:______________________________

MARGARET L. HUTCHINSON
Chief, Civil Division
United States Attorney’s Office
Eastern District of Pennsylvania

DATED:_______  BY:______________________________

COLIN CHERICO
Assistant U.S. Attorney
United States Attorney’s Office
Eastern District of Pennsylvania

DATED: 4/27/10  BY:______________________________

PATRICIA L. HANOWER
Trial Attorney
Commercial Litigation Branch
Civil Division
United States Department of Justice
Settlement Agreement Between United States and AstraZeneca, Inc.

DATED: 4/27/10

BY:

GREGORY E. DEMSKE
Assistant Inspector General for Legal Affairs
Office of Counsel to the Inspector General
Office of Inspector General
United States Department of Health and Human Services

DATED: ________

BY:

LAUREL C. GILLESPIE
Deputy General Counsel
TRICARE Management Activity
United States Department of Defense

DATED: ________

BY:

SHIRLEY R. PATTERSON
Acting Deputy Associate Director Insurance Operations
Center for Retirement & Insurance Services
United States Office of Personnel Management

DATED: ________

BY:

DAVID COPE
Debarring Official
Office of the Assistant Inspector General for Legal Affairs
United States Office of Personnel Management

Settlement Agreement Between United States and AstraZeneca, Inc.

-18-
DATED:_______  BY:________________________
GREGORY E. DEMSKE
Assistant Inspector General for Legal Affairs
Office of Counsel to the Inspector General
Office of Inspector General
United States Department of Health and Human Services

DATED:April 23, 2010  BY:________________________
For: LAUREL C. GILLESPIE
Deputy General Counsel
TRICARE Management Activity
United States Department of Defense

DATED:_______  BY:________________________
SHIRLEY R. PATTERSON
Acting Deputy Associate Director Insurance Operations
Center for Retirement & Insurance Services
United States Office of Personnel Management

DATED:_______  BY:________________________
DAVID COPE
Debarring Official
Office of the Assistant Inspector General for Legal Affairs
United States Office of Personnel Management

Settlement Agreement Between
United States and AstraZeneca, Inc.

-18-
DATED:__________  BY: ____________________________
GREGORY E. DEMSKE
Assistant Inspector General for Legal Affairs
Office of Counsel to the Inspector General
Office of Inspector General
United States Department of Health and Human Services

DATED:__________  BY: ____________________________
LAUREL C. GILLESPIE
Deputy General Counsel
TRICARE Management Activity
United States Department of Defense

DATED: 4/26/10  BY: ____________________________
SHIRLEY R. PATTERSON
Acting Deputy Associate Director Insurance Operations
Center for Retirement & Insurance Services
United States Office of Personnel Management

DATED: 4/26/10  BY: ____________________________
DAVID COPE
Debarring Official
Office of the Assistant Inspector General for Legal Affairs
United States Office of Personnel Management
ASTRAZENECA

DATED: 4/27/10

BY: [Signature]
Glenn M. Engelmann
Vice President and General Counsel
AstraZeneca LP
AstraZeneca Pharmaceuticals LP

DATED: 4/27/10

BY: [Signature]
John C. Dodds, Esq.
Morgan, Lewis and Bockius, LLP

Settlement Agreement Between
United States and AstraZeneca, Inc.

-19-
RELATOR JAMES WETTA

DATED: _____ BY: __________________________

JAMES WETTA

DATED: _____ BY: __________________________

STEPHEN A. SHELLER, ESQ.

(Counsel to Relator James Wetta)
RELATOR JAMES WETTA

DATED: 1/23/10
BY: James Wetta by Michael Mustokoff
JAMES WETTA

DATED: 4/23/10
BY: Stephen A. S eller
STEPH EN A. S ELLE R, ES Q.
(Counsel to Relator James Wetta)

BY: Michael Mustokoff
MARK LIPO WICZ
TERESA CAVENAGH
DUANE MORRIS, LLP

BY: G a ry M. Farmer Jr.
FARMER JAFFE WEISSING EDWARDS FISTOS AND LEHRMAN
RELATOR STEPHAN KRUSZEWSKI

DATED: 4/23/2010  
BY: STEPHAN KRUSZEWSKI

DATED: 1/23/10  
BY: WILLIAM LEONARD, ESQUIRE
(Counsel to Stephan Kruszewski)
RELATOR STEPHAN KRUSZEWKI

DATED:_______  BY:__________________________
               STEFAN KRUSZEWSKI

DATED:4/23/10  BY:__________________________
               WILLIAM LEONARD, ESQUIRE
               (Counsel to Stephan Kruszewski)